The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...

The dosage of Lantus is individualized and depends on several factors, such as the type of diabetes being treated, your body weight, blood sugar goals, and response to treatment. Lantus is given as a ...

Semglee and Insulin Glargine may now be substituted for the reference product Lantus (insulin glargine) at the pharmacy counter. Viatris Inc. and Biocon Biologics have announced the launch of ...

Of the more than 30 million Americans with diabetes, about 7.4 million use one or more forms of supplemental insulin to help keep their blood sugar levels within a certain target range. Insulin ...

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- For the first time today, Eli Lilly and Company (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals Inc. presented data showing that LY2963016, the ...

Lantus, a long-acting insulin glargine, offers stable 24-hour blood sugar control for people with type 1 and type 2 diabetes. It is often introduced when other treatments are insufficient, and can be ...

Tresiba (insulin degludec) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat type 1 and type 2 diabetes in ...

In March of this year the three largest insulin manufacturers announced a dramatic reduction in the price of many commonly prescribed insulins and a monthly out-of-pocket (OOP) cap of $35 that went ...

Amid consumer angst and political pressure over the cost of life-saving insulin, Sanofi announced Thursday it would slash the price of its most-prescribed insulin, Lantus. Sanofi said it will cut the ...

Technically, there is no official “generic” insulin. However, several newer unbranded insulins have been introduced in recent years. These are both fast-acting bolus insulin and long-acting basal ...